Tag Archives: SAGE

Cowen & Co. Keeps a Buy Rating on SAGE Therapeutics (SAGE)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $96.00. The company’s shares closed last Monday at $61.02, close to its 52-week low of $56.50.

Morgan Stanley Keeps Their Buy Rating on SAGE Therapeutics (SAGE)

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) on November 21 and set a price target of $217.00. The company’s shares closed last Monday at $149.00. According to TipRanks.com, Harrison is a

H.C. Wainwright Initiates a Hold Rating on SAGE Therapeutics (SAGE)

SAGE Therapeutics (SAGE – Research Report) received a Hold rating and a $160.00 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed last Monday at $140.16. According to TipRanks.com, Tsao is a 1-star analyst with an

Oppenheimer Keeps Their Buy Rating on SAGE Therapeutics (SAGE)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $170. The company’s shares closed on Friday at $167.34, close to its 52-week high of

SAGE Therapeutics (SAGE) Receives a Buy from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) yesterday and set a price target of $170. The company’s shares closed yesterday at $165.52, close to its 52-week high of $177.14. Olson said: “SAGE

The CFO & Treasurer of SAGE Therapeutics is Exercising Options

Today it was reported that the CFO & Treasurer of SAGE Therapeutics (SAGE – Research Report), Kimi Iguchi, exercised options to buy 4,723 SAGE shares at $0.45 a share, for a total transaction value of $2,125. This recent transaction increases